Oral 31:Cardiovascular (PYP) 1

[2-MO31-3] Quantitative evaluation of^99mTc-PYP in cardiac amyloidosis patients receiving tafamidis

Shin Yanagisawa¹、Yukinori Okajima¹、Tsuneaki Yashinaga²、Nagaaki Katoh²、Masatoshi Minamisawa³、Yoshiki Sekijima²、Yasunari Fujinaga¹ (1.Department of Radiology, Shinshu University School of Medicine, Matsumoto, Japan、2.Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan、3.Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan)